MitoCareX Bio ^{For Profit}

MitoCareX Bio is a drug discovery company that develops therapies for hard-to-treat resistant cancers by targeting Mitochondrial Carriers. The company utilizes its generated knowledge and know-how in the field for potentially targeting each of the 53 human Mitochondrial Carriers. They use their cloud-based computational chemistry platform and MITOLINE™ algorithm to model, predict and discover small molecules that target Mitochondrial Carriers. MitoCareX Bio has developed its MITOLINE™ algorithm and other advanced computational capabilities to generate reliable 3D models for its mitochondrial proteins of interest. They tailor cell-based and cell-free bioassays with specific readouts to validate and monitor the activity of their virtual hit molecules. The company was founded in 2022 and their contact information is available on their website.